Search
Search
Close this search box.
Search
Close this search box.

Jury Orders Abbott to Pay $495M in Baby Formula NEC Trial

A jury last week ordered Abbott Laboratories to pay $495 million in damages to the mother of a girl who developed necrotizing enterocolitis (NEC) after consuming Similac baby formula as a premature infant. This verdict sheds light on the potential health risks associated with cow’s milk-based formulas for preterm babies, particularly the devastating intestinal disease, NEC. The jury trial, which concluded with this substantial monetary award, has drawn attention to the ongoing debate about the safety of certain infant formulas and their link to gastrointestinal diseases in premature infants.

Baby Formula NEC Verdict Details and Implications

The landmark infant formula NEC verdict was delivered by a Missouri jury on July 26, 2024, in the claim of Gill v. Abbott Laboratories. The jury found Abbott liable for negligent design, failure to warn, and strict liability. This decision marks a significant turning point in the ongoing litigation surrounding baby formula and its potential link to necrotizing enterocolitis (NEC) in premature infants.

The jury awarded a substantial sum of $495 million in damages to the plaintiff, Margo Gill, and her daughter Robynn. This amount comprises $95 million in compensatory damages and $400 million in punitive damages, which underscores the jury’s intent to punish Abbott and deter similar conduct in the future. 

The verdict against Abbott has far-reaching implications for the baby formula industry and families affected by necrotizing enterocolitis, highlighting the growing calls for accountability from formula manufacturers and setting a powerful precedent for future NEC-related lawsuits.

Understanding NEC and its Link to Infant Formula Products

What is NEC?

Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease primarily affecting premature infants. It causes inflammation and tissue death in the intestines, potentially leading to intestinal perforation. NEC typically manifests within the first 2-4 weeks of life and can progress rapidly from mild feeding intolerance to systemic sepsis. In advanced cases, surgery may be necessary to remove necrotic intestinal tissue, and tragically, up to 30% of NEC cases can result in infant mortality.

Potential Risk Factors for NEC

Premature birth is the most significant risk factor for NEC, with 90% of cases occurring in infants born before 37 weeks gestation. Low birth weight (less than 5.5 pounds) and enteral nutrition through stomach tubes also increase the risk of NEC. The immature immune and digestive systems of preterm infants make them more susceptible to intestinal infections and diminished blood flow to the intestines.

Cow’s Milk-Based Baby Formulas and NEC

The link between cow’s milk-based formulas and NEC has become a subject of controversy and legal action. Studies have shown that premature infants fed with cow’s milk formulas, such as Similac and Enfamil, have a significantly higher risk of developing NEC compared to those fed with human milk exclusively. Despite this knowledge, manufacturers like Abbott Laboratories have been accused of not providing adequate warnings about the risk of NEC associated with their products. This has led to numerous lawsuits alleging negligence and failure to warn consumers about the potential dangers of these formulas for premature infants.

Abbott’s Response to the Verdict and Future Legal Challenges

Abbott Laboratories has strongly disputed the claims made against them in the recent NEC lawsuit. The company maintains that its baby formula is essential for feeding premature infants who cannot breastfeed. An Abbott spokesperson argued that specialized formulas and fortifiers are among the only available options to feed premature infants and stated that there is no scientific evidence showing that Abbott’s preterm infant products cause or contribute to causing NEC. Abbott has announced its intention to appeal the verdict.

Lawsuits Alleging NEC from Baby Formula

This recent verdict against Abbott Laboratories is part of a growing trend of product liability lawsuits against baby formula manufacturers. Close to 1,000 lawsuits have been filed against Abbott and other companies, including Reckitt Benckiser and Mead Johnson, the manufacturers of Enfamil. According to the most recent MDL statistics report, more than 500 of these lawsuits are part of federal multidistrict litigation in Illinois, with the initial bellwether trial scheduled for May 2025.

Baby Formula NEC Lawsuit Information

Baby formula NEC lawsuits are alleging a link between cow's milk-based baby formula brands like Similac and Enfamil and an increased risk of necrotizing enterocolitis. Learn more by clicking on the button.
FREE
author avatar
Faith Anderson
Facebook
Twitter
Pinterest
LinkedIn
Reddit
WhatsApp

Related Posts

Breast Milk May Lower Asthma Risk Compared to Infant Formula: Study

New research reveals a potential connection between infant feeding methods and childhood asthma risk. A comprehensive study comparing breast milk and infant formula has shown that babies who receive exclusive breastfeeding may face lower risks of developing asthma during their early years. The American Academy of Pediatrics notes this finding

Similac NEC Lawsuit Filed Over Infant’s Sepsis, GI Injuries

A mother from Michigan has raised serious allegations in a lawsuit concerning the potential adverse effects of Similac infant formula on her premature newborn. The mother, Shalona Smith, claims that her son, referred to in the claim as R.S.J., developed sepsis and other severe complications from necrotizing enterocolitis (NEC) after

Abbott, Reckitt Face Trial Over Alleged Baby Formula NEC Risks

The use of cow’s milk-based baby formula for premature infants has come under intense scrutiny in recent years, with a growing number of lawsuits alleging that these products put vulnerable newborns at risk of developing a severe intestinal condition known as necrotizing enterocolitis (NEC). As the legal battles continue to

Scroll to Top